In this Healio Video Perspective, Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, discusses EYP-1901 for the treatment of wet age-related macular degeneration.
Duker shares an update on efficacy and safety data from the phase 1 DAVIO trial, presented at Angiogenesis, Exudation, and Degeneration 2022.